Researchers in Japan have reported early results from a first-in-human clinical trial that gave children with cerebral palsy infusions of stem cells taken from their own baby teeth. It's one of the clearest examples yet of the idea behind dental stem cell banking: a child's own baby tooth cells, given back to that child.
What the study found
- Safety: The infusions were well tolerated, with no acute reactions or infusion-related side effects.
- Motor function: Children's scores on a standard measure of motor function rose by an average of 3.2 points at 12 weeks and kept climbing across all patients through 52 weeks.
- Next steps: As a Phase I trial, the study's main goal was safety. Larger trials will be needed to confirm the benefits.
Early results, peer review pending. The results were posted as a preprint in November 2026, meaning they haven't yet completed peer review. We'll share an update when the final paper is published.
Why it matters
This trial used each child's own stem cells, collected from their baby teeth. That's exactly the kind of future use that banking makes possible. It builds on earlier research in which baby tooth stem cells regrew living tissue inside children's injured teeth, and on the FDA's 2024 approval of the first therapy from this family of stem cells.
Processed and stored in an FDA-registered, AABB-accredited laboratory.


